Y-mAbs/YMAB

$11.60

-2.1%
-
1D1W1MYTD1YMAX

About Y-mAbs

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.

Ticker

YMAB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Rossi

Employees

100

Headquarters

New york, United States

Y-mAbs Metrics

BasicAdvanced
$534M
Market cap
-
P/E ratio
-$0.50
EPS
0.69
Beta
-
Dividend rate
$534M
0.69161
$20.90
$4.60
376K
6.15
5.67
-16.62%
-20.93%
-19.95%
6.325
5.385
5.53
12.62%
70.66%
59.89%

What the Analysts think about Y-mAbs

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
82.24% upside
High $26.00
Low $12.00
$11.60
Current price
$21.14
Average price target

Y-mAbs Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-33.16% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$20M
-14.59%
Net income
-$6.6M
633.33%
Profit margin
-33.16%
759.07%

Y-mAbs Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 10.46%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.14
-$0.18
-$0.02
-$0.15
-
Expected
-$0.24
-$0.19
-$0.20
-$0.14
-$0.12
Surprise
-42.07%
-3.67%
-90.05%
10.46%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Y-mAbs stock?

Y-mAbs (YMAB) has a market cap of $509M as of May 20, 2024.

What is the P/E ratio for Y-mAbs stock?

The price to earnings (P/E) ratio for Y-mAbs (YMAB) stock is 0 as of May 20, 2024.

Does Y-mAbs stock pay dividends?

No, Y-mAbs (YMAB) stock does not pay dividends to its shareholders as of May 20, 2024.

When is the next Y-mAbs dividend payment date?

Y-mAbs (YMAB) stock does not pay dividends to its shareholders.

What is the beta indicator for Y-mAbs?

Y-mAbs (YMAB) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Y-mAbs stock price target?

The target price for Y-mAbs (YMAB) stock is $21.14, which is 82.24% above the current price of $11.6. This is an average based on projections from 7 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Y-mAbs stock

Buy or sell Y-mAbs stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing